{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:47:34Z","timestamp":1785235654994,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026137","name":"Aviation Distributors and Manufacturers Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaip.2025.05.059","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:46:01Z","timestamp":1751903161000},"page":"2590-2599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Facilitated Subcutaneous Immunoglobulin 10% Safety Among Pediatric Patients With Primary Immunodeficiency Diseases"],"prefix":"10.1016","volume":"13","author":[{"given":"Niraj C.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolan E.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.05.059_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41232-021-00159-6","article-title":"Inborn errors of immunity\u2014recent advances in research on the pathogenesis","volume":"41","author":"Yamashita","year":"2021","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.jaip.2025.05.059_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1710-1492-7-S1-S11","article-title":"Primary immunodeficiency","volume":"7","author":"McCusker","year":"2011","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJM199508173330707","article-title":"The primary immunodeficiencies","volume":"333","author":"Rosen","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.05.059_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/idoj.IDOJ_189_17","article-title":"Approach to a child with primary immunodeficiency made simple","volume":"8","author":"Sharma","year":"2017","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaip.2025.05.059_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780140","article-title":"The PID principles of care: where are we now? A global status report based on the PID life index","volume":"12","author":"Nordin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/imt-2017-0092","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases","volume":"9","author":"Wasserman","year":"2017","journal-title":"Immunother"},{"key":"10.1016\/j.jaip.2025.05.059_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","article-title":"Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again","volume":"32","author":"Wasserman","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2025.05.059_bib10","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3389\/fimmu.2018.01925","article-title":"Limited innovations after more than 65 years of immunoglobulin replacement therapy: potential of IgA- and IgM-enriched formulations to prevent bacterial respiratory tract infections","volume":"9","author":"Langereis","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib11","series-title":"Immune globulin subcutaneous","year":"2006"},{"key":"10.1016\/j.jaip.2025.05.059_bib12","first-page":"S98","article-title":"Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin","volume":"25","author":"Ness","year":"2019","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaip.2025.05.059_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13223-022-00726-7","article-title":"A clinician\u2019s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases","volume":"18","author":"Epland","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.827305","article-title":"Primary immune deficiency: patients\u2019 preferences for replacement immunoglobulin therapy","volume":"13","author":"Gonzalez","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib15","article-title":"immune globulin infusion 10% (human) with recombinant human hyaluronidase","year":"2024","journal-title":"Highlights of prescribing information"},{"key":"10.1016\/j.jaip.2025.05.059_bib16","article-title":"HyQvia 100 mg\/mL solution for infusion for subcutaneous use","year":"2024","journal-title":"Summary of product characteristics"},{"key":"10.1016\/j.jaip.2025.05.059_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/NAN.0000000000000182","article-title":"Practical considerations for self-administration of subcutaneous immunoglobulin G utilizing recombinant human hyaluronidase, an advanced method of subcutaneous administration: a nurse\u2019s perspective","volume":"39","author":"Miars","year":"2016","journal-title":"J Infus Nurs"},{"key":"10.1016\/j.jaip.2025.05.059_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2025.05.059_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10875-018-0507-x","article-title":"Rapid push vs pump-infused subcutaneous immunoglobulin treatment: a randomized crossover study of quality of life in primary immunodeficiency patients","volume":"38","author":"Bienvenu","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) therapy \u2013 practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib39","article-title":"Cuvitru 200 mg\/ml solution for subcutaneous injection","year":"2022","journal-title":"Summary of product characteristics"},{"key":"10.1016\/j.jaip.2025.05.059_bib51","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13223-022-00746-3","article-title":"Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes","volume":"18","author":"Mallick","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-023-01632-2","article-title":"A phase 1 open-label study to assess the tolerability, safety, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin 20% in healthy adults","volume":"44","author":"Nagy","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10875-025-01862-6","article-title":"Efficacy, safety, tolerability, and serum IgG trough levels of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency diseases","volume":"45","author":"Patel","year":"2025","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/imt-2021-0167","article-title":"Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases","volume":"14","author":"Baumann","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaip.2025.05.059_bib58","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10875-023-01470-2","article-title":"Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: the FIGARO study","volume":"43","author":"Borte","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib59","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12325-020-01264-7","article-title":"Clinical practice experience with HyQvia in adults using alternative dosing regimens and pediatric patients: a retrospective study","volume":"37","author":"Wasserman","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2025.05.059_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13223-024-00904-9","article-title":"fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study","volume":"20","author":"\u010ci\u017en\u00e1r","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000534900","article-title":"Facilitated subcutaneous immunoglobulin treatment increases the quality of life and decreases the number of infections and hospitalizations in children with primary immunodeficiencies","volume":"185","author":"Erba\u015f A\u00e7\u0131c\u0131","year":"2024","journal-title":"Int Arch Allerg Appl Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/imt-2023-0305","article-title":"Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases","volume":"16","author":"Mach-Tomalska","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaip.2025.05.059_bib63","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","article-title":"Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency","volume":"36","author":"Wasserman","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib64","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2016-0066","article-title":"Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability","volume":"8","author":"Wasserman","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaip.2025.05.059_bib65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clim.2008.08.003","article-title":"Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita","volume":"129","author":"Tayal","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib66","author":"Sloan"},{"key":"10.1016\/j.jaip.2025.05.059_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12881-015-0177-y","article-title":"A patient with polymerase E1 deficiency (POLE1): clinical features and overlap with DNA breakage\/instability syndromes","volume":"16","author":"Thiffault","year":"2015","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jaip.2025.05.059_bib68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"10.1016\/j.jaip.2025.05.059_bib69","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1208\/s12248-015-9782-0","article-title":"Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration","volume":"17","author":"Rosengren","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.jaip.2025.05.059_bib70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12248-022-00757-3","article-title":"Risk factors, hyaluronidase expression, and clinical immunogenicity of recombinant human hyaluronidase PH20, an enzyme enabling subcutaneous drug administration","volume":"24","author":"Printz","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.jaip.2025.05.059_bib71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.05.059_bib72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40259-018-0260-y","article-title":"Recombinant human PH20: baseline analysis of the reactive antibody prevalence in the general population using healthy subjects","volume":"32","author":"Rosengren","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaip.2025.05.059_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825005367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825005367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:23:40Z","timestamp":1777116220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825005367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2213219825005367"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.059","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Facilitated Subcutaneous Immunoglobulin 10% Safety Among Pediatric Patients With Primary Immunodeficiency Diseases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.05.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}